Seres Therapeutics Inc (MCRB) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $50. H.C. Wainwright advised their investors in a research report released on Jul 29, 2016.
On the company’s financial health, Seres Therapeutics Inc reported $-0.50 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on May 16, 2016. Analyst had a consensus of $-0.46. The company had revenue of $2.70 million for the quarter, compared to analysts expectations of $.83 million.
Seres Therapeutics Inc opened for trading at $35.23 and hit $35.98 on the upside on Thursday, eventually ending the session at $35.77, with a gain of 1.94% or 0.68 points. The heightened volatility saw the trading volume jump to 1,89,751 shares. Company has a market cap of $1,414 M.
In a different news, on Jul 28, 2016, Roger Pomerantz (President and CEO) sold 20,000 shares at $35.00 per share price. According to the SEC, on Jul 28, 2016, Michele Trucksis (Chief Medical Officer and EVP) sold 38,064 shares at $35.14 per share price. On Jun 30, 2016, Eric D. Shaff (CFO and EVP) sold 4,533 shares at $29.54 per share price, according to the Form-4 filing with the securities and exchange commission.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.